News Releases | Tarsus Pharmaceuticals

Year

Jun 12, 2023

Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis

Webcast scheduled for Thursday, June 15 at 8:30am PT IRVINE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care,

Jun 05, 2023

Tarsus to Present at the Jefferies Global Healthcare Conference

IRVINE, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., Chief

May 09, 2023

Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements

Continuing to build market awareness through disease education and deploying commercial leadership in anticipation of TP-03 August 25, 2023 PDUFA Presented health economics data suggesting a costly and substantial burden of illness in patients with Demodex blepharitis Tarsus to host investor

May 08, 2023

Tarsus Launches “Don’t Freak Out. Get Checked Out.” Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers

Demodex blepharitis is a highly prevalent, yet often undiagnosed eyelid disease that impacts approximately 25 million eye care patients in the U.S. IRVINE, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven

May 03, 2023

Tarsus to Participate at the Bank of America 2023 Healthcare Conference

IRVINE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., Chief

Apr 24, 2023

Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer

IRVINE, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Jeff Farrow as

Mar 13, 2023

Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements

Engaging with more than two-thirds of key optometrists and/or ophthalmologists, and top payers on Demodex blepharitis in anticipation of TP-03 August 25, 2023 PDUFA Completed enrollment of Ersa, a Phase 2a trial evaluating TP-03 for MGD with topline data expected in 2H 2023 and initiated Galatea

Mar 02, 2023

Tarsus to Present at Upcoming Investor Conferences

IRVINE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that management will participate at

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 18 of 18